ZEN003694 (ZEN-3694)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ZEN003694 (ZEN-3694), covering 2026-04-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer [Phase 1]